Tags Archive Navigation
icon
-
StoryExpanding a new digital healthcare solution across chronic heart disease management
-
Media ReleaseNovartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
-
Media ReleaseNovartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu
-
Media ReleaseNovartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben
-
Media ReleaseNovartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
-
Media ReleaseNovartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
-
Media ReleaseNovartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Media ReleaseSandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
-
Media ReleaseNovartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 9
- › Next page